SOURCE: Equity Markets Inc

October 04, 2011 09:00 ET

US Domestic, Global Economic Outlook - Equity Research on DaVita Inc. and NxStage Medical, Inc.

MACAU--(Marketwire - Oct 4, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting DaVita Inc. (NYSE: DVA) and NxStage Medical, Inc. (NASDAQ: NXTM). Full content and research is available at www.EquityMarketsInc.com/research.php?id=DVA+NXTM.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed DaVita Inc. for its current position within the healthcare industry. DaVita Inc. is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, which is an end stage renal disease (ESRD). It provides hospital inpatient hemodialysis services, excluding physician services, to patients in approximately 750 hospitals. The full research report on DaVita Inc. (NYSE: DVA) is available here: www.EquityMarketsInc.com/research.php?id=DVA.

Equity Markets has reviewed NxStage Medical, Inc. for its development within the healthcare industry. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its primary product includes the NxStage System One (the System One). NxStage operates in two segments: System One and In-Center. The full research report on NxStage Medical, Inc. (NASDAQ: NXTM) is available here: www.EquityMarketsInc.com/research.php?id=NXTM.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information